Cloud-Connected Automated Intravenous (IV) Compounding Market Forecast 2026–2030: Market Size, Trends And Growth Opportunities
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Cloud-Connected Automated Intravenous (IV) Compounding Market Poised To Hit $5.03 Billion By 2030 With A 16.5% CAGR
The cloud-connected automated intravenous (IV) compounding market size has experienced rapid growth in recent years. It is projected to increase from $2.34 billion in 2025 to $2.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.8%. This historical expansion can be attributed to several factors: the increasing adoption of automated IV compounding systems, a growing demand for medication safety and accuracy, rising hospital investments in pharmacy automation, the expansion of oncology and specialized treatment centers, and a growing awareness of sterile compounding standards.
The cloud-connected automated intravenous (IV) compounding market is projected to experience swift expansion in the coming years. This market is anticipated to reach $5.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.5%. Several factors contribute to this growth during the forecast period, including the increased adoption of cloud-based monitoring solutions, the advancement of AI-powered error detection systems, greater investment in compact and modular robotic designs, the broadening of homecare and decentralized pharmacy applications, and a stronger emphasis on interoperability and data analytics platforms. Key trends projected for this period encompass technological enhancements in cloud-connected workflow management, breakthroughs in AI and machine learning for predictive compounding, the creation of smart consumables and sensors, intensified research and development into oncology-specific automation solutions, and significant investment in scalable and remote monitoring deployment models.
Get A Free Sample Report With In-Depth Market Insights:
Cloud-Connected Automated Intravenous (IV) Compounding Market Expansion Drivers: What’s Shaping Future Growth?
The escalating demand for biosimilars is projected to propel the expansion of the cloud-connected automated IV compounding market in the foreseeable future. Biosimilars are biologic medical products that exhibit high similarity to an already approved reference biologic, demonstrating no clinically meaningful differences in safety, purity, or efficacy. The heightened demand for biosimilars is attributable to their cost-effectiveness when compared to branded biologics. Automated IV compounding plays a vital role in enhancing the safe and accurate preparation of biosimilars by reducing human error, ensuring precise dosing, and upholding product integrity. For instance, according to Cardinal Health Inc., a US-based healthcare company, it was reported in January 2023 that, as of January 2022, the U.S. had 33 FDA-approved biosimilar products, with 21 available on the market, and by 2023, this figure increased to 40 FDA-approved biosimilars, with 25 of them commercially accessible. Thus, the growing demand for biosimilars is a significant driver for the cloud-connected automated IV compounding market.
Cloud-Connected Automated Intravenous (IV) Compounding Market Segments: Where Is Growth Concentrated?
The cloud-connected automated intravenous (iv) compounding market covered in this report is segmented –
1) By Product Type: Robotic Compounding Systems, Software Solutions, Consumables
2) By Deployment Mode: Cloud-Hosted Deployment, Hybrid Cloud Deployment, On-Premise With Cloud Integration
3) By Application: Hospital Pharmacies, Oncology Centers, Homecare Settings, Other Applications
4) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Robotic Compounding Systems: Automated Intravenous Preparation Robots, Modular Robotic Compounding Units, Sterile Compounding Robotic Arms, Integrated Safety Monitoring Systems
2) By Software Solutions: Workflow Management Software, Inventory Management Software, Dose Verification Software, Remote Monitoring And Analytics Software
3) By Consumables: Sterile Syringes, Intravenous Bags, Vials And Ampoules, Filters And Tubing Sets, Protective Personal Equipment
Cloud-Connected Automated Intravenous (IV) Compounding Market Strategic Trends: What Defines The Next Growth Phase?
Major companies operating in the cloud-connected automated intravenous (IV) compounding market are concentrating on enhancing automated systems, such as cloud-enabled monitoring and compliance tracking, to improve sterile preparation accuracy, reduce medication errors, and strengthen regulatory adherence. Cloud-enabled monitoring and compliance tracking refers to integrated software and hardware features that permit healthcare facilities to access real-time data on IV compounding processes, maintain electronic audit trails, and ensure adherence to sterility and quality standards across multiple sites. For instance, in May 2025, the United States Food and Drug Administration (FDA), a US-based regulatory authority, highlighted updated guidance and enforcement initiatives under section 503B of the Federal Food, Drug, and Cosmetic Act, which require outsourcing facilities to maintain rigorous quality control and documentation for compounded sterile products. These guidelines encourage the adoption of automated IV compounding systems with cloud-based monitoring, electronic record-keeping, and remote quality oversight capabilities.
Cloud-Connected Automated Intravenous (IV) Compounding Market Top Companies Driving Competitive Growth
Major companies operating in the cloud-connected automated intravenous (iv) compounding market are McKesson Corporation, Becton Dickinson and Company, Baxter International Inc., B. Braun Melsungen SE, Fresenius Kabi AG, Grifols S.A., ICU Medical Inc., Syntegon Technology GmbH, Omnicell Inc., Marchesini Group S.p.A., Swisslog Healthcare, ScriptPro LLC, Parata Systems LLC, ARxIUM Inc., Equashield LLC, Health Robotics S.r.l., Rommelag AG, NewIcon Oy, DoseEdge, Aesynt Inc.
View The Full Cloud-Connected Automated Intravenous (IV) Compounding Market Report:
Cloud-Connected Automated Intravenous (IV) Compounding Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the cloud-connected automated intravenous (IV) compounding market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cloud-connected automated intravenous (iv) compounding market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model